News Allergy Tx plots grass pollen jab launch after German okay Allergy Therapeutics has had its grass pollen allergy treatment Grassmuno approved in Germany, its first market, setting up a launch early next year.
News Allergy Therapeutics suffers phase 3 birch allergy jab trial... UK-based Allergy Therapeutics has suffered a setback after phase 3 results from the B301 trial of its latest birch allergy product failed to reduce symptoms.
Views & Analysis UK biotech round-up: Autolus joins CAR-T race, Horizon’s new... Three small, innovative firms demonstrate the diversity and promise of the UK bioscience sector.
Oncology LSX2026: Addressing adult eye cancer, with Roi Raz Roi Raz, CEO of ReBio Pharma, discusses injectable, bioresorbable sustained release delivery for ophthalmic therapeutics at LSX 2026.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.